Q3FY2019 Results
Can anyone please explain why CL Rathi left the management of company. And why he has been selling his holdings continuously.yesterday also he sold about 5 percent through his holding companies
Where did you read this?
Is he selling ? could you provide the source ? They have to intimate exchange after selling > 5% as they are promoters.
@AmitContrarian , AFAIK promoter has to inform of any selling or buying irrespective of the percentage. However they can do this within few days of the selling and not necessarily the same day.
For info on selling by Mr. CL , Refer 8th Mar bulk deals and you would see the data.
Check the bulk deal reports of 8th march
Any idea why prices shoot up in last 2 days? if promoters are selling then prices should fall isn’t it?
@ [mohammadarshad27] : from where did u get info that C L Rathi left management of company?
bandhu…Promoter sold to bring in Orbimed Asia III Mauritius Limited. Promoter nearly sold around 10 % which was bought entirely by this fund house. And now go read on about Orbimed Asia.
1 Like
Update
The promoters completely removed the pledge this quarter.
https://www.bseindia.com/corporates/shpSecurities.aspx?scripcd=540025&qtrid=102.00
| Quarter | Pledge% |
|---|---|
| Mar 2018 | 39.49% |
| Jun 2018 | 26.61% |
| Sep 2018 | 30.10% |
| Dec 2018 | 15.34% |
| Mar 2019 | 12.52% |
| Jun 2019 | ------ |
5 Likes
Any one has data on following -
Revenue as a percentage -
Geographically Vs India ?
B2B Vs B2C ?
% of revenue from top 5 customers ?
Who are those customers ?
Do they have any monopoly on products they sell ?
Thanks,
Amit
Promoter entity Atharva Green Ecotech LLP bought 629,000 Equity Shares in Advanced Enzyme Technologies Ltd. at an average price of Rs. 167.3
I was wondering why such a big amount of goodwill in the balance sheet…!
of the recent purchase they acquired JC Biotech for 500million Rs.
Evoxx Technologies GmbH for 600mn.
but the goodwill amounts stands over 2700mn.
and recently ORBIMED ASIA III MAURITIUS acquired stake from the promoters.
these are biopharma investors, their only investment in india is in this company…
why didnt they buy from the market? what impression does this carry to u?
a similar activity of promoter selling to hdfc amc was seen earlier in 2018
its very strange the promoters sell to institutions, at higher prices then themselves rebuy at lower prices form the market, meanwhile release pledged shares, then agian raise debt at promoter level which dosent come in the bc , the subsidiaries are not audited by their chief auditors, and an intricate network of subsidiaries…
thank you.
6 Likes
These are all very valid questions and thats why company trades at the valuations it do, question is are things changing w.r.t promoters behaviour, There are lots of evidence yes they are changing.
MD/ CEO changed.
Pledge is gone.
Disclosures - in AR or otherwise have improved.
No more foolish forecasting during conf calls.
etc.
Conference call highlights-
Management is expecting to meet the lower range of its revenue growth guidance (i.e. 10-
13% provided earlier) for FY20 due to some challenges in foreign markets while maintaining
43-45% EBITDA margin guidance.
Evoxx’s total EBITDA in Q2FY20 grew 59% yoy to Rs13mn from Rs8.2mn in Q1FY20.
Revenue stood at Rs58mn vs. Rs56mn in Q1FY20.
Palm oil to remain a long-waiting process, which is why the company has closed its
Malaysian subsidiary due to unwanted expenses arising.
RM cost is higher qoq due to change in the segment mix.
Other equity increased due to the translation into Indian currency.
Top client contribution stood at 14% vs. 14% Q1FY20.
Management expects India region to be a growth contributor in H2FY20
R&D expenses for the quarter stood at Rs40mn.
At an optimum level, the company can double its revenues with the existing capacity. The
current capacity utilization is ~50%.
3 Likes
Advanced Enzymes Q2 Result Update!
https://drive.google.com/open?id=1Gu9WLtg55KyriYbPpDRCyxJThez-mt9y
Prepared by E-Global Group of Companies!
https://www.e-global.in/about-us/#Endeavour_Wealth_Management
(Disclaimer: Not an Investment/Trading Recommendation)
2 Likes
These guys don’t know the numbers on the top of their head, Listen to conf. call. For every silly question like how much this subsidiary do they start turning pages, whispering something etc.
It always gives me this strange feeling how come a CEO don’t know these basic numbers and truly a business can be run by average management if all reported numbers are true.
2 Likes
Please provide some proof to support your thesis of judging the management by reading their expressions. List down the companies in which your feelings had been similar and the numbers later were found to be false.
1 Like
Hey Amit ,
in recent interview they told there top client makes 14% of revenue .
